March 11 (Reuters) - Acadia Pharmaceuticals ( ACAD )
said on Monday its experimental drug to treat negative symptoms
of schizophrenia failed to meet the main goal in a late-stage
study.
(Reporting by Mariam Sunny in Bengaluru)